Xilio Therapeutics (XLO) Announces Pipeline Updates, Reports Q3 Reults

Go back to Xilio Therapeutics (XLO) Announces Pipeline Updates, Reports Q3 Reults

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

December 2, 2021 7:30 AM EST

Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022

Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4

Successfully Closed IPO in Fourth Quarter of 2021, Raising Approximately $130 Million in Gross Proceeds to Advance Pipeline of Tumor-Selective Immuno-Oncology Programs

WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today reported recent pipeline and business progress and third quarter 2021 financial results.

Xilio made significant... More